Weighing Costs, Benefits Of HIV Treatments
Tuesday, September 15, 2009 - 13:35
in Health & Medicine
Prevention versus treatment? Cost versus efficacy? So go two of the dilemmas looming over researchers in the race to fight HIV and other infectious diseases in the developing world — especially among women and their young children. A randomized trial found that a cohort of 82 HIV-infected children ages 6 to 35 months responded better to treatment with the protease-inhibiting drug lopinavir (LPV/r) than did a cohort of 82 children in the same age group who received the anti-retroviral drug nevirapine (NVP).